Scribd Logo
Upload

Welcome to Scribd!

  • 72 views

    Justification

    Uploaded by

    Stephanie Joy Escala
    The document discusses the justification for focusing on developing a dengue vaccine in the Philippines. Dengue has been a major problem in the country since 1953, with the Philippines being one of the top countries affected. From 2008-2012 there were over 585,000 reported cases of dengue in the country. The city of Cagayan de Oro in Mindanao has the highest number of cases, with over 1,600 cases and 7 deaths from January to September 2016. After 20 years of research, a company called Sanofi Pasteur developed the first licensed dengue vaccine called Dengvaxia, which became available in the Philippines in 2016. The Department of Health has been using it in schools in high incidence

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Justification

    Uploaded by

    Stephanie Joy Escala
    72 views2 pages
    The document discusses the justification for focusing on developing a dengue vaccine in the Philippines. Dengue has been a major problem in the country since 1953, with the Philippines being one of the top countries affected. From 2008-2012 there were over 585,000 reported cases of dengue in the country. The city of Cagayan de Oro in Mindanao has the highest number of cases, with over 1,600 cases and 7 deaths from January to September 2016. After 20 years of research, a company called Sanofi Pasteur developed the first licensed dengue vaccine called Dengvaxia, which became available in the Philippines in 2016. The Department of Health has been using it in schools in high incidence

    Original Description:

    Shots Fired! A Fight Against the Bite

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The document discusses the justification for focusing on developing a dengue vaccine in the Philippines. Dengue has been a major problem in the country since 1953, with the Philippines being one of the top countries affected. From 2008-2012 there were over 585,000 reported cases of dengue in the country. The city of Cagayan de Oro in Mindanao has the highest number of cases, with over 1,600 cases and 7 deaths from January to September 2016. After 20 years of research, a company called Sanofi Pasteur developed the first licensed dengue vaccine called Dengvaxia, which became available in the Philippines in 2016. The Department of Health has been using it in schools in high incidence

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    72 views2 pages

    Justification

    Uploaded by

    Stephanie Joy Escala
    The document discusses the justification for focusing on developing a dengue vaccine in the Philippines. Dengue has been a major problem in the country since 1953, with the Philippines being one of the top countries affected. From 2008-2012 there were over 585,000 reported cases of dengue in the country. The city of Cagayan de Oro in Mindanao has the highest number of cases, with over 1,600 cases and 7 deaths from January to September 2016. After 20 years of research, a company called Sanofi Pasteur developed the first licensed dengue vaccine called Dengvaxia, which became available in the Philippines in 2016. The Department of Health has been using it in schools in high incidence

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 2

    V.

    JUSTIFICATION
    Dengue has been rampant in the Philippines since 1953. The group decided to

    tackle dengue vaccine as it could potentially decrease the high number of cases of

    dengue, here in the Philippines. It is a timely manner to discuss dengue since rainy days

    already started and the rainy season brings perfect breeding conditions for the

    mosquitoes.

    According to the United Nations University, Philippines is the top 7 country with the

    highest cases of dengue. From 2008 to 2012, the Philippines' Department of Health

    (DOH) reported 585,324 dengue cases, with a case fatality rate (CFR) of 0.55% or 3,195

    deaths.

    In Mindanao, according to Sunstar (2016), Cagayan de Oro has the highest

    number of dengue cases. From January 2016 to September 2016, the number of cases

    reached up to 1619 cases and 7 deaths were reported. According to Sergio Ramon

    Bautista, the officer in charge of the Environmental Sanitation Office, he said that they

    are anticipating that the 2016 toll of dengue patients will be greater than 2015s which

    only went up to 1,934 with only four deaths. The top 10 barangays with the highest

    number of dengue cases are Carmen, Kauswagan, Balulang, Lumbia, Bulua, Lapasan,

    Macasandig, Bugo, Patag, and Canitoan.

    There is no treatment for Dengue Fever, however, after 20 years of research,

    Sanofi Pasteur, a French company, has developed the first dengue vaccine called

    Dengvaxia. The company will be taking the product directly to the countries that are most

    affected by dengue fever and marketing it there. The dengue vaccine is classified as a

    live recombinant tetravalent. It is a preparation of killed viruses, used to protect against


    organisms that were injected. And now, it is available in the Philippines. According to CNN

    (2016), the Philippines is the first country where the vaccine will be made commercially

    available. The Department of Health (DOH) has been conducting vaccinations in public

    schools in three regions where the incidence of dengue is high. As of June 2017, the DOH

    Region 7 held a dengue vaccine orientation and aims to give the vaccine to 470, 000

    children, who are age 9 to 14.

    The topic is entitled, Shots Fired! The Fight Against the Bite. After how many

    years of fighting dengue, the target has been finally hit, a vaccine that could potentially

    reduce the number of dengue cases has been developed, which is Dengvaxia. The group

    aims to spread awareness and update the beneficiaries about the dengue vaccine. As of

    now, both the company who made the vaccine, Sanofi and the vaccine itself, Dengvaxia

    are facing a lot of issues such as the long-term safety and side effects of the vaccine and

    Sanofi is now facing a problem with the Food and Drug Administration (FDA) regarding

    their promotional advertisements. The group aims to notify the beneficiaries about these

    issues as well as the pros and cons of taking the vaccine so that they will be

    knowledgeable about its benefits and the probable problems that they will be facing in the

    future. Our knowledgeable speakers from the Department of Health Region 10 will give

    all information to ensure validity and reliability. They will also discuss what will be the

    future plans of the DOH with regards to the dengue vaccination.

    You might also like